Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.67 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.42 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770083 | 0.98 | PLA2G2A (0.67) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL5769684 | 0.92 | PLA2G2A (0.64) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL5766359 | 0.90 | PLA2G2A (0.64) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6691907 | 0.83 | PLA2G2A (0.60) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6312131 | 0.82 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6398151 | 0.82 | PLA2G2A (0.50) | PLA2G2AFABP4 | |
| SCHEMBL6393255 | 0.82 | PLA2G2A (0.47) | PLA2G2AFABP4 | |
| SCHEMBL6695147 | 0.81 | PLA2G2A (0.58) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6392622 | 0.81 | PLA2G2A (0.50) | PLA2G2AFABP4 | |
| SCHEMBL6697348 | 0.81 | PLA2G2A (0.57) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | claimed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | claimed |
| US-6872743-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | claimed |
| US-20040063941-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | claimed |
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-6872743-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040063941-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063941-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | PLA2G2A 26/4885PLA2G10 19/4885PLA2G1B 15/4885 |
| US-20040092543-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | PLA2G2A 23/4885PLA2G10 15/4885PLA2G1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.